Shares of bluebird bio (NASDAQ:BLUE) have rebounded in the past year, up close to 80% in a remarkable turn of investor sentiment in this midcap biotech company.

The name came back to my attention after listening in to the upbeat presentation by CEO Nick Leschly at the JP Morgan Healthcare Conference. He mentions that the company is now pivoting to focus on a longer term future in 2022 and how they will progress their promising gene therapy (and oncology) pipeline.

